TFBS Bioscience, Inc.

AusBiotech wrapped up successfully—huge thanks to all the partners who made this week a success! Special appreciation to BPIPO MOEA-IDA for the seamless arrangements and to Centre for Eye Research Australia (CERA) for the thoughtful coordination. It was a memorable week filled with new connections and opportunities. We look forward to continued follow-up and seeing everyone again in Australia soon! #AusBiotech2025 #Biotech #TFBS #GlobalPartnership #Australia #BusinessDevelopment

🔔 TFBS Bioscience at CERA: Advancing Taiwan–Australia Biotech Collaboration We were honored to participate in key biotech events at the Centre for Eye Research Australia (CERA), a leading institute for ophthalmic and biotech research:  • Oct 20 – BioConnect: Australia–Taiwan Biotech Networking BD Director Shao-Hua Lo presented TFBS Bioscience's capabilities in viral vector CDMO and CRO testing for Cell and Gene Therapy (CGT) products.  • Oct 21 – Taiwan–Australia Biotechnology Development Forum (TSAA AGM) CEO Thomas Yuan joined as a distinguished panellist, sharing insights on biotech development and internati events strengthened connections with industry leaders and fostered opportunities in the CGT field. #TFBSBioscience #CellAndGeneTherapy #CDMO #CRO #BiotechCollaboration #TaiwanAustralia #CGT

🔔 TFBS Bioscience Inc. is excited to be part of AusBiotech 2025! We'll be at Booth #99, Taiwan Pavilion, MCEC Melbourne — on Wed. October 22, 2025. We specialize in Cell and Gene Therapy (CGT) solutions — with a strong focus on viral vector manufacturing and preclinical testing. From R&D to commercial stages, we support CGT developers with quality-driven, regulatory-compliant services. Let's connect and explore potential collaborations! 👉 Meet our BD Director Shao-Hua Lo at the booth! #AusBiotech2025 #CellandGeneTherapy #Biopharmaceuticals #CGT #RegenerativeMedicine #ViralVectors #AAV #Lentivirus #TFBS #Melbourne

What a great week at BioJapan 2025! 🎉 It was wonderful meeting so many friends and discussing exciting new opportunities. Huge thanks to TFBS Taiwan and Japan team for all the hard work and passion that made it happen! See you all next time! 👋 #BioJapan2025 #TFBSBioscience #CDMO #CRO #CellAndGeneTherapy #Collaboration #TeamTFBS

🌟 Heading to Yokohama for BioJapan 2025 from October 8–10! 🌟 Visit us at Booth# B-91 to meet our team and explore how #TFBS can support your advanced therapy and biologics programs through our integrated CRO and CDMO solutions. We look forward to connecting with both long-standing partners and new collaborators at this exciting event. Let us catch up, exchange ideas, and explore new opportunities together at #BioJapan2025! 📍 BioJapan 2025 🗓️ October 8–10, 2025 📌 Booth B-91 ーーーーーーーーーーーーーーーーーーー TFBSはBioJapan2025に出展します。 10月8～10日＠パシフィコ横浜で開催されます。 ブース番号「B-91」に是非お立ち寄りください。

U-Medico Inc. and TFBS Bioscience, Inc. are pleased to announce that they have entered into a business alliance focused on quality analysis. Leveraging our advanced analytical expertise and TFBS Bioscience’s strength in viral clearance studies and biosafety testing, we will jointly provide GMP QC testing services for viral vectors to clients worldwide.

🔔TFBS Bioscience x U-Medico Strategic Alliance We are excited to announce our strategic partnership with U-Medico Inc. to jointly launch GMP QC testing services for viral vectors and CGT therapeutics across Japan, Taiwan, and the Asia-Pacific region. This collaboration combines: 🔹 U-Medico’s advanced analytical technologies – including Analytical Ultracentrifugation (AUC) and Mass Photometry for precise viral vector characterization. 🔹 TFBS Bioscience’s expertise in biology-based assays, biosafety testing, and GMP viral vector manufacturing. Together, we provide a one-stop QC solution that supports regulatory submissions in Japan PMDA, US FDA, and Taiwan TFDA, accelerating the development of innovative gene and cell therapies with enhanced safety and quality assurance. With this alliance, TFBS Bioscience and U-Medico aim to establish a center of excellence for QC testing in Asia, helping transformative therapies reach patients faster. 🔗 Learn more: https://lnkd.in/gBFnkwYY #U-Medico #TFBS #CellAndGeneTherapy #ViralVector #GMP #QualityControl #StrategicPartnership #Biotech #Japan #Taiwan

🔔TFBS Bioscience x artiCure Collaboration Announcement We are excited to announce that TFBS Bioscience has entered into a strategic collaboration with artiCure, a Korea-based biotech company pioneering multimodal cancer gene therapies. Together, we will advance retroviral vector GMP manufacturing to accelerate clinical trials of cancer gene therapies in Korea. This partnership combines artiCure's innovative retroviral platform with TFBS Bioscience's end-to-end viral vector CDMO and GMP/GLP testing CRO services, marking a new milestone for Korea–Taiwan collaboration in the cell and gene therapy field. 🔹 TFBS Bioscience: Taiwan's first and only GMP-grade viral vector CDMO 🔹 artiCure: Driving next-generation multimodal gene therapies for hard-to-treat cancers We look forward to contributing to the growth of Asia's CGT ecosystem and advancing innovative solutions for patients worldwide. Learn more: https://lnkd.in/gGv-RA6K #artiCure #TFBS #CancerTherapy #RetroviralVector #CellandGeneTherapy #ViralVector #CDMO #Oncology #Biotech #Collaboration

🔔TFBS Bioscience x artiCure Collaboration Announcement We are excited to announce that TFBS Bioscience has entered into a strategic collaboration with artiCure, a Korea-based biotech company pioneering multimodal cancer gene therapies. Together, we will advance retroviral vector GMP manufacturing to accelerate clinical trials of cancer gene therapies in Korea. This partnership combines artiCure's innovative retroviral platform with TFBS Bioscience's end-to-end viral vector CDMO and GMP/GLP testing CRO services, marking a new milestone for Korea–Taiwan collaboration in the cell and gene therapy field. 🔹 TFBS Bioscience: Taiwan's first and only GMP-grade viral vector CDMO 🔹 artiCure: Driving next-generation multimodal gene therapies for hard-to-treat cancers We look forward to contributing to the growth of Asia's CGT ecosystem and advancing innovative solutions for patients worldwide. Learn more: https://lnkd.in/gGv-RA6K #artiCure #TFBS #CancerTherapy #RetroviralVector #CellandGeneTherapy #ViralVector #CDMO #Oncology #Biotech #Collaboration

JSGCT 2025 Day 1 in Tokyo is underway! Come visit our partner, メディリッジ株式会社 (Mediridge Co., Ltd) booth, where you can meet our Business Directors, Yutaka Mitsuo and Shao-Hua Lo, along with the Mediridge team. We look forward to sharing more about our capabilities in regenerative medicine services. See you there! #JSGCT2025 #RegenerativeMedicine #TFBS #CellTherapy #Genetherapy #Virualvector #CDMO #Collaboration